Meeting
2015 Gastrointestinal Cancers Symposium
Highly sensitive quantitative detection of circulating tumor DNA in urine and plasma from advanced colorectal cancer patients in aid of early diagnosis of clinically relevant KRAS mutations.
Authors
Jason C. Poole
Trovagene, San Diego, CA
Jason C. Poole , Cecile Rose T. Vibat , Lucie Benesova , Barbora Belsanova , Saege Hancock , Timothy Lu , Mark Erlander , Marek Minarik
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 654)
DOI
10.1200/jco.2015.33.3_suppl.654
Abstract #
654
Poster Bd #
C46
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Mutation enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced colorectal and other cancers.
First Author: Filip Janku
Poster
2015 ASCO Annual Meeting
Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers.
First Author: Filip Janku
Poster
2018 ASCO Annual Meeting
High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib.
First Author: Pashalina Kehagias
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer.
First Author: Khalid Jazieh